

Title (en)
COMPOSITIONS OF BERBERINE URSODEOXYCHOLATE AND METHODS THEREOF FOR TREATING FATTY LIVER DISEASE, DIABETES AND HYPERLIPIDEMIA

Title (de)
ZUSAMMENSETZUNGEN AUS BERBERIN-URSODEOXYCHOLAT UND VERFAHREN DAFÜR ZUR BEHANDLUNG VON FETTLBERERKRANKUNG, DIABETES UND HYPERLIPIDÄMIE

Title (fr)
COMPOSITIONS DE BERBÉRINE URSODÉSOXYCHOLATE ET MÉTHODES ASSOCIÉES POUR LE TRAITEMENT DE STÉATOSE HÉPATIQUE, DE DIABÈTE ET D'HYPERLIPIDÉMIE

Publication
EP 4232045 A4 20240904 (EN)

Application
EP 21882127 A 20211022

Priority
• US 202063104754 P 20201023
• CN 2021125490 W 20211022

Abstract (en)
[origin: WO2022083713A1] The invention provides pharmaceutical compositions of berberine ursodeoxycholate (BUDCA) and methods of use thereof for the treatment fatty liver disease, diabetes and hyperlipidemia, and related diseases and conditions.

IPC 8 full level
A61K 31/575 (2006.01); **A61K 9/20** (2006.01); **A61K 9/48** (2006.01); **A61K 31/4375** (2006.01); **A61P 1/16** (2006.01); **A61P 3/06** (2006.01); **A61P 3/10** (2006.01)

CPC (source: EP)
A61K 31/4375 (2013.01); **A61K 31/575** (2013.01); **A61P 1/16** (2018.01); **A61P 3/06** (2018.01); **A61P 3/10** (2018.01); **A61K 9/20** (2013.01); **A61K 9/48** (2013.01)

C-Set (source: EP)
1. **A61K 31/4375 + A61K 2300/00**
2. **A61K 31/575 + A61K 2300/00**

Citation (search report)
• [XY] WO 2016015634 A1 20160204 - SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTD [CN]
• [Y] WO 2009011420 A1 20090122 - MITSUBISHI TANABE PHARMA CORP [JP], et al
• [Y] WO 2010106420 A1 20100923 - AXCAN PHARMA INC [CA], et al
• [XY] LIU L ET AL: "HTD1801 a novel treatment addressing the underlying metabolic features of NAFLD/NASH", HEPATOLOGY V70 SUPPL.1 2019 20191001 JOHN WILEY AND SONS INC. NLD, vol. 70, no. Supplement 1, 1 October 2019 (2019-10-01), XP009555841, ISSN: 1527-3350
• [XY] LIU, LP; BAI, R; YU, L; YU, M; FU, XX: "HTD1801 A NOVEL TREATMENT FOR NAFLD/NASH AND PRIMARY SCLEROSING CHOLANGITIS (PSC)", HEPATOLOGY, vol. 70, no. Suppl 1, 1 October 2019 (2019-10-01), pages 1261A - 1262A, XP009555813
• [Y] XING LIAN-JUN ET AL: "Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 668, no. 3, 1 October 2011 (2011-10-01), NL, pages 467 - 471, XP093189113, ISSN: 0014-2999, DOI: 10.1016/j.ejphar.2011.07.036
• [Y] LI ZHAO ET AL: "Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease", BMC ENDOCRINE DISORDERS, BIOMED CENTRAL LTD, LONDON, UK, vol. 17, no. 1, 28 February 2017 (2017-02-28), pages 1 - 8, XP021242660, DOI: 10.1186/S12902-017-0165-7
• [Y] ZHANG HAO ET AL: "Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression", METABOLISM, vol. 59, no. 2, 1 February 2010 (2010-02-01), US, pages 285 - 292, XP093189125, ISSN: 0026-0495, DOI: 10.1016/j.metabol.2009.07.029
• See also references of WO 2022083713A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2022083713 A1 20220428; CN 116782898 A 20230919; EP 4232045 A1 20230830; EP 4232045 A4 20240904

DOCDB simple family (application)
CN 2021125490 W 20211022; CN 202180072375 A 20211022; EP 21882127 A 20211022